FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 302 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer October 26, 2021 FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer July 4, 2025 Her Wedding Ceremony Was Interrupted By A Voice In The Back,... March 25, 2019 EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide August 9, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Akeega, Fixed-Dose Combinations of... EMA Adopts a Positive Opinion for Biosimilar Denosumab EMA Starts Review of Rucaparib COVID-19 May Have Saved a Woman’s Life by Helping Her Discover...
